CRC is the third most commonly diagnosed malignancy and the fourth leading cause of
cancer-related death in the world. With advances in treatment, colorectal cancer is being …

This selection from the NCCN Guidelines for Rectal Cancer focuses on management of
malignant polyps and resectable nonmetastatic rectal cancer because important updates …

PURPOSE Prospective data on the efficacy of a watch-and-wait strategy to achieve organ
preservation in patients with locally advanced rectal cancer treated with total neoadjuvant …

Colorectal cancer (CRC) is a major contributor to cancer-associated morbidity worldwide
and over one-third of CRC is located in the rectum. Neoadjuvant chemoradiotherapy (nCRT) …

The number of deaths from colorectal cancer in Japan continues to increase. Colorectal
cancer deaths exceeded 50,000 in 2016. In the 2019 edition, revision of all aspects of …

The American Society of Colon and Rectal Surgeons (ASCRS) is dedicated to ensuring high-
quality patient care by advancing the science, prevention, and management of disorders …

Rectal cancer (RC) is a challenging disease to treat that requires chemotherapy, radiation
and surgery to optimize outcomes for individual patients. No accurate model of RC exists to …

The incidence of rectal cancer in the European Union is $125 000 per year, ie $35% of the
total colorectal cancer incidence, reflecting 15–25 cases/100000 population per year and is …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Rectal Cancer
address diagnosis, staging, surgical management, perioperative treatment, management of …

PURPOSE In the multicenter, open-label, phase III FOWARC trial, modified infusional
fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus radiotherapy resulted in a higher …